• Je něco špatně v tomto záznamu ?

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations

JA. Witjes, M. Babjuk, P. Gontero, D. Jacqmin, A. Karl, S. Kruck, P. Mariappan, J. Palou Redorta, A. Stenzl, R. van Velthoven, D. Zaak,

. 2014 ; 66 (5) : 863-71. [pub] 20140704

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000704

CONTEXT: Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC). Hexaminolevulinate (HAL) is an optical-imaging agent used with blue-light cystoscopy (BLC) in NMIBC diagnosis. Increasing evidence from long-term follow-up confirms the benefits of BLC over WLC in terms of increased detection and reduced recurrence rates. OBJECTIVE: To provide updated expert guidance on the optimal use of HAL-guided cystoscopy in clinical practice to improve management of patients with NMIBC, based on a review of the most recent data on clinical and cost effectiveness and expert input. EVIDENCE ACQUISITION: PubMed and conference searches, supplemented by personal experience. EVIDENCE SYNTHESIS: Based on published data, it is recommended that BLC be used for all patients at initial TURBT to increase lesion detection and improve resection quality, thereby reducing recurrence and improving outcomes for patients. BLC is particularly useful in patients with abnormal urine cytology but no evidence of lesions on WLC, as it can detect carcinoma in situ that is difficult to visualise on WLC. In addition, personal experience of the authors indicates that HAL-guided BLC can be used as part of routine inpatient cystoscopic assessment following initial TURBT to confirm the efficacy of treatment and to identify any previously missed or recurrent tumours. Health economic modelling indicates that the use of HAL to assist primary TURBT is no more expensive than WLC alone and will result in improved quality-adjusted life-years and reduced costs over time. CONCLUSIONS: HAL-guided BLC is a clinically effective and cost-effective tool for improving NMIBC detection and management, thereby reducing the burden of disease for patients and the health care system. PATIENT SUMMARY: Blue-light cystoscopy (BLC) helps the urologist identify bladder tumours that may be difficult to see using standard white-light cystoscopy (WLC). As a result, the amount of tumour that is surgically removed is increased, and the risk of tumour recurrence is reduced. Although use of BLC means that the initial operation costs more than it would if only WLC were used, over time the total costs of managing bladder cancer are reduced because patients do not need as many additional operations for recurrent tumours.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000704
003      
CZ-PrNML
005      
20160125110834.0
007      
ta
008      
160108s2014 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2014.06.037 $2 doi
035    __
$a (PubMed)25001887
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Witjes, J Alfred $u Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: fred.witjes@radboudumc.nl.
245    10
$a Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations / $c JA. Witjes, M. Babjuk, P. Gontero, D. Jacqmin, A. Karl, S. Kruck, P. Mariappan, J. Palou Redorta, A. Stenzl, R. van Velthoven, D. Zaak,
520    9_
$a CONTEXT: Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC). Hexaminolevulinate (HAL) is an optical-imaging agent used with blue-light cystoscopy (BLC) in NMIBC diagnosis. Increasing evidence from long-term follow-up confirms the benefits of BLC over WLC in terms of increased detection and reduced recurrence rates. OBJECTIVE: To provide updated expert guidance on the optimal use of HAL-guided cystoscopy in clinical practice to improve management of patients with NMIBC, based on a review of the most recent data on clinical and cost effectiveness and expert input. EVIDENCE ACQUISITION: PubMed and conference searches, supplemented by personal experience. EVIDENCE SYNTHESIS: Based on published data, it is recommended that BLC be used for all patients at initial TURBT to increase lesion detection and improve resection quality, thereby reducing recurrence and improving outcomes for patients. BLC is particularly useful in patients with abnormal urine cytology but no evidence of lesions on WLC, as it can detect carcinoma in situ that is difficult to visualise on WLC. In addition, personal experience of the authors indicates that HAL-guided BLC can be used as part of routine inpatient cystoscopic assessment following initial TURBT to confirm the efficacy of treatment and to identify any previously missed or recurrent tumours. Health economic modelling indicates that the use of HAL to assist primary TURBT is no more expensive than WLC alone and will result in improved quality-adjusted life-years and reduced costs over time. CONCLUSIONS: HAL-guided BLC is a clinically effective and cost-effective tool for improving NMIBC detection and management, thereby reducing the burden of disease for patients and the health care system. PATIENT SUMMARY: Blue-light cystoscopy (BLC) helps the urologist identify bladder tumours that may be difficult to see using standard white-light cystoscopy (WLC). As a result, the amount of tumour that is surgically removed is increased, and the risk of tumour recurrence is reduced. Although use of BLC means that the initial operation costs more than it would if only WLC were used, over time the total costs of managing bladder cancer are reduced because patients do not need as many additional operations for recurrent tumours.
650    _2
$a kyselina aminolevulová $x analogy a deriváty $x ekonomika $7 D000622
650    _2
$a analýza nákladů a výnosů $7 D003362
650    _2
$a cystektomie $x ekonomika $x metody $x normy $7 D015653
650    _2
$a cystoskopie $x ekonomika $x metody $x normy $7 D003558
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    12
$a náklady na zdravotní péči $7 D017048
650    _2
$a lidé $7 D006801
650    _2
$a ekonomické modely $7 D018803
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a reziduální nádor $7 D018365
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a kvalita života $7 D011788
650    _2
$a kvalitativně upravené roky života $7 D019057
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory močového měchýře $x ekonomika $x patologie $x chirurgie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Babjuk, Marek $u Department of Urology, Motol Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Gontero, Paolo $u Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
700    1_
$a Jacqmin, Didier $u Department of Urology, Strasbourg University Hospital, Strasbourg, France.
700    1_
$a Karl, Alexander $u Department of Urology, Ludwig Maximilians University, Munich, Germany.
700    1_
$a Kruck, Stephan $u Department of Urology, Eberhard Karls University, Tübingen, Germany.
700    1_
$a Mariappan, Paramananthan $u Department of Urology, Western General Hospital, Edinburgh, UK.
700    1_
$a Palou Redorta, Juan $u Urologic Oncology Unit, Department of Urology, Puigvert Foundation, Barcelona, Spain.
700    1_
$a Stenzl, Arnulf $u Department of Urology, Eberhard Karls University, Tübingen, Germany.
700    1_
$a van Velthoven, Roland $u Department of Urology, Jules Bordet Institute, Brussels, Belgium.
700    1_
$a Zaak, Dirk $u Department of Urology, Traunstein Hospital, Traunstein, Germany.
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 66, č. 5 (2014), s. 863-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25001887 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160125110956 $b ABA008
999    __
$a ok $b bmc $g 1102985 $s 924910
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 66 $c 5 $d 863-71 $e 20140704 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Možnosti archivace